De Castiglia S G, Duran A, Fiszman G, Horenstein A L
Oncologic Center of Nuclear Medicine, National Atomic Energy Commission, Buenos Aires, Argentina.
Nucl Med Biol. 1995 Apr;22(3):367-72. doi: 10.1016/0969-8051(94)00097-4.
The anti-carcinoembryonic B2C114 monoclonal antibody was radiolabeled with 99mTc by a direct method and quality control tested in vitro by instant thin layer chromatography, gel column scanning and cellulose acetate electrophoresis and assessed in vivo for radioimmunodetection on a murine spontaneous mammary carcinoma. The optimal results of percent 99mTc bound to protein were obtained at a dithiothreitol:antibody molar ratio ranging from 800:1 to 1000:1 and at a methylene diphosphonate:stannous fluoride weight ratio of 4.3:1. Although cysteine removed up to 18% of the label during the first 4 h, the stability of the tracer appeared to be excellent in human serum at 37 degrees C and when challenged with DTPA. 99mTc-labeled B2C114 demonstrated good and specific in vivo tumor targeting.
采用直接法用99mTc对癌胚抗原B2C114单克隆抗体进行放射性标记，并通过即时薄层色谱法、凝胶柱扫描法和醋酸纤维素电泳法在体外进行质量控制检测，并在体内对小鼠自发性乳腺癌进行放射免疫检测评估。在二硫苏糖醇与抗体的摩尔比为800:1至1000:1以及亚甲基二膦酸盐与氟化亚锡的重量比为4.3:1时，获得了与蛋白质结合的99mTc百分比的最佳结果。尽管半胱氨酸在最初4小时内去除了高达18%的标记物，但该示踪剂在37℃的人血清中以及用二乙三胺五乙酸（DTPA）激发时稳定性似乎极佳。99mTc标记的B2C114在体内显示出良好且特异的肿瘤靶向性。
